Global Tuberculosis (TB) Drugs/Therapeutics Market Analysis & Trends - Industry Forecast to 2027

Global Tuberculosis (TB) Drugs/Therapeutics Market Analysis & Trends - Industry Forecast to 2027

  • May 2018 •
  • 196 pages •
  • Report ID: 5443526 •
  • Format: PDF
The Global Tuberculosis (TB) Drugs/Therapeutics Market is poised to grow strong during the forecast period 2017 to 2027.

Some of the prominent trends that the market is witnessing include increased focus on TB vaccine development and rising the emergence of drug-resistant TB.

Based on Type, the market is categorized into Latent Tuberculosis, Active Tuberculosis and Drug-resistant Tuberculosis.

Depending on Drug Class the market is segregated into First-Line Anti-TB Drugs, Second-Line Anti-TB Drugs and Combination Drugs. In addition, First-Line Anti-TB Drugs is further segmented into Isoniazid, Ethambutol, Pyrazinamide, Rifampicin, Rifabutin, Streptomycin and Other First-Line Anti-TB Drugs. Second-Line Anti-TB Drugs is divided into Cycloserine, Moxifloxacin, Gatifloxacin, Amikacin/Kanamycin, Ethionamide, Capreomycin and Other Second-Line Anti-TB Drugs.
On the basis of Product, the market is bifurcated into Hydrazine derivatives, Isoniazid, Miscellaneous anti tubercular Drugs, Rifampin, Ethambutol and Pyrazinamide.

Based on End User, the market is categorized into Hospital Pharmacies, Ambulatory Surgical Centers and Individual Pharmacies.